PEMF — Pulsed Electromagnetic Field Therapy

Evidence-supportedBgradePlausibility · PlausibleElectromagnetic Field

The mainstream anchor of the electromagnetic family: a real induction mechanism with regulatory clearance for specific orthopedic and neuropsychiatric indications, routinely over-extended into unsupported general-wellness claims.

Origin & lineage

Modern electromagnetic therapy; FDA-cleared for non-union fracture in 1979.

Claimed mechanism

Pulsed magnetic fields induce Faraday currents that modulate Ca²⁺/calmodulin signalling, adenosine receptors, and bone / inflammation pathways.

Plausibility

Plausible — classical electromagnetic induction with defined dosimetry (field strength, frequency, pulse width).

Evidence — grade B

A for the FDA-cleared bone/pain indications; low-GRADE for osteoarthritis; weak for off-label / systemic claims.

Market

Makers: Orthofix; Swiss Bionic Solutions (iMRS); Curatron; MagnaWave.
Models: PhysioStim, Cervical-Stim; iMRS mats; MagnaWave units.
Price: Home/consumer mats ~$1–6K; iMRS ~$2–8K; MagnaWave ~$10K+.

Kernel — keep vs set aside

Keep — real substrate

Real, measurable mechanism — time-varying magnetic fields inducing tissue currents at a quantified dose. The narrow cleared indications are justified.

Set aside — claim

Off-label extrapolation to broad 'whole-body healing' or anti-aging is not supported by the cleared-indication evidence.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDA	Class II/III cleared — non-union fracture, post-op pain, cervical fusion; depression via rTMS.
EU — MDR	CE IIa/IIb.
Russia	Registered (Roszdravnadzor).
China — NMPA	Registered.
Australia — TGA	Listed (ARTG).

PEMF — Pulsed Electromagnetic Field Therapy

Kernel — keep vs set aside

Regulatory status by jurisdiction

Sources